<DOC>
	<DOCNO>NCT02322216</DOCNO>
	<brief_summary>The purpose study evaluate olopatadine 0.2 % QD ( per day ) compare olopatadine 0.1 % BID ( twice per day ) treatment ocular itching associate allergic conjunctivitis .</brief_summary>
	<brief_title>Olopatadine Hydrochloride Ophthalmic Solution Study Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Chinese ethnicity ; History allergic conjunctivitis within last 2 year ; Positive skin prick test skin intradermal test document lab report within 24 month , baseline visit ; Clinical diagnosis allergic conjunctivitis specific sign symptom ; Understand sign inform consent form ; Willing able make require study visit follow study instruction , comply dose study medication instruct ; Other protocolspecified inclusion criterion may apply . Contraindications hypersensitivity study medication component ; Bestcorrected visual acuity ( BCVA ) score bad 55 ETDRS letter ( equivalent approximately 0.60 logMAR , 20/80 Snellen , 0.25 decimal ) either eye ; Any ocular condition could affect study outcome ; Presumed actual ocular infection history ocular herpes either eye ; Known history retinal detachment , diabetic retinopathy , progressive retinal disease ; Willing able avoid use topical ocular medication ( ) ( include artificial tear product ) ; Any significant illness could expect interfere study , particularly autoimmune disease ; Intraocular surgery either eye within 6 month , ocular laser surgery either eye within 3 month , anticipation ocular surgery study ; ocular trauma either eye within 3 month baseline visit ; Clinically relevant recent ( within 6 month baseline visit ) history current severe , unstable , uncontrolled cardiovascular , pulmonary , hepatic , renal , autoimmune disease relevant systemic disease would preclude safe administration topical antihistamine/mast cell stabilizer opinion Investigator ; Use systemic medication ( ) chronic dose regimen less 1 month change dosage within month prior baseline visit ; Use disallow medication ( topical , topical ophthalmic , systemic and/or injectable ) period indicate prior baseline visit . These medication also allow study . Disallowed medication include antiallergy therapy include contain prescription overthecounter sleep aid ; Use cold compress eye course study ; Can dose eye ; Can avoid contact lens wear course study ; Therapy another investigational agent within 30 day baseline visit , study ; Women childbearing potential pregnant , intend become pregnant study period , breastfeeding , use adequate birth control method ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Allergies</keyword>
	<keyword>Ocular</keyword>
</DOC>